• Autonomix Medical received U.S. Patent No. 12,433,670 for systems and methods to treat cancer or augment organ function.
• Patent covers minimally invasive catheter-based tools to sense and map nerve activity, then guide targeted neuromodulation or delivery of therapeutic agents.
• Protection extends to selectively targeting tumor-associated nerves linked to cancer-related pain, organ function, autonomic nervous system disorders.
• Company highlighted potential use across solid tumors such as pancreatic, prostate, breast cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040815PRIMZONEFULLFEED9802949) on August 04, 2026, and is solely responsible for the information contained therein.